Nemaura Medical Launches Beta Version of Its Metabolic Health Program
September 29 2021 - 8:30AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or “the Company”),
a medical technology company focused on developing and
commercializing noninvasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, announces the
beta launch of MiBoKo, a new metabolic health program utilizing a
noninvasive glucose sensor along with an AI mobile application.
Dr. Faz Chowdhury, Nemaura’s Chief Executive
Officer, will discuss MiBoKo in more detail during his corporate
presentation scheduled for today, September 29, 2021 at 11:10 a.m.
ET during the Benzinga Healthcare Small Cap Conference. Investors
can access this presentation by registering for the conference at
https://www.benzinga.com/events/small-cap/healthcare/
MiBoKo, which has been in development for the
past 18 months, addresses a significant mass market opportunity
that the Company believes could benefit roughly a third to half of
the population by using a noninvasive glucose sensor to measure and
monitor a user’s metabolic health score, which is based on glucose
tolerance or insulin resistance. Those with prediabetes or obesity
concerns, or even those looking to maintain better health through
more careful glucose control, could benefit from such a metabolic
health program.
MiBoKo’s next-level health tracking program uses
a small and comfortable sensor and a mobile app to provide users
with personalized information by tracking their metabolism. A user
can find out how well their body responds to sugar through their
metabolic health score — and how what they eat and what they do
every day uniquely affects their metabolic health.
“A person’s response to sugar intake can
influence a number of factors from appetite and body weight to
sleep patterns, energy levels, and even mood, not to mention also
being a considerable factor in chronic diseases like diabetes,
heart disease and dementia,” explains Dr. Chowdhury. “With MiBoKo,
we are able to extend our proprietary noninvasive device and sensor
technology and interactive lifestyle and AI coaching programs
beyond the traditional diabetes market and into an adjacent, yet
separate, market application of metabolic health. At Nemaura, we
continue to look for the intersection of patient comfort and
convenience through advanced and unique technology that addresses
significant healthcare needs for large patient populations. We
believe that MiBoKo offers insights into metabolic health in a
user-friendly way unlike any other program on the market.”
Along with the capability to follow metabolic
health progress on an app, a MiBoKo user receives weekly and
monthly reports that show and explain their body’s unique metabolic
health score and a breakdown of how each of their habits are
impacting their overall health and wellbeing. Suggestions for
small, manageable changes to daily routines, such as eating more or
less of a certain kind of food or exercising at a different time of
day to coincide with peak energy levels, provide MiBoKo users with
personalized, usable data.
Anyone interested in participating as a MiBoKo
user can now register for the beta program at www.MiBoKo.com. There
is no cost during the beta period, with approved MiBoKo beta
testers receiving the sensors and AI program free of charge. The
initial beta launch is intended for North America, the U.K. and
Europe. Further details of the program can be found at
www.MiBoKo.com.
About Nemaura Medical,
Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing noninvasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a noninvasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and prediabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines noninvasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service that has been launched in the U.S. as a general wellness
product as part of its BEAT® diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion prediabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024